FI850140L - Kemiska foereningar. - Google Patents

Kemiska foereningar.

Info

Publication number
FI850140L
FI850140L FI850140A FI850140A FI850140L FI 850140 L FI850140 L FI 850140L FI 850140 A FI850140 A FI 850140A FI 850140 A FI850140 A FI 850140A FI 850140 L FI850140 L FI 850140L
Authority
FI
Finland
Prior art keywords
compounds
formula
foereningar
chemical
chemical foereningar
Prior art date
Application number
FI850140A
Other languages
English (en)
Finnish (fi)
Other versions
FI850140A7 (fi
FI850140A0 (fi
Inventor
Robert Antony Slater
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of FI850140A0 publication Critical patent/FI850140A0/fi
Publication of FI850140A7 publication Critical patent/FI850140A7/fi
Publication of FI850140L publication Critical patent/FI850140L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
FI850140A 1984-01-13 1985-01-11 Kemiska foereningar. FI850140L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Publications (3)

Publication Number Publication Date
FI850140A0 FI850140A0 (fi) 1985-01-11
FI850140A7 FI850140A7 (fi) 1985-07-14
FI850140L true FI850140L (fi) 1985-07-14

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
FI850140A FI850140L (fi) 1984-01-13 1985-01-11 Kemiska foereningar.

Country Status (31)

Country Link
US (1) US4654342A (de)
EP (1) EP0150937B1 (de)
JP (3) JPS60158181A (de)
KR (1) KR920006781B1 (de)
CN (1) CN85101722A (de)
AT (1) ATE37179T1 (de)
AU (1) AU572252B2 (de)
CA (2) CA1251209A (de)
CS (1) CS248731B2 (de)
DD (1) DD231350A5 (de)
DE (1) DE3564941D1 (de)
DK (1) DK162519C (de)
ES (3) ES8607949A1 (de)
FI (1) FI850140L (de)
GB (1) GB8400863D0 (de)
GR (1) GR850068B (de)
HU (1) HU193591B (de)
IE (1) IE57969B1 (de)
IL (1) IL74031A (de)
JO (1) JO1351B1 (de)
MY (1) MY100124A (de)
NO (1) NO850129L (de)
NZ (1) NZ210816A (de)
PH (1) PH22136A (de)
PL (1) PL147123B1 (de)
PT (1) PT79819B (de)
RO (1) RO92607A (de)
SU (1) SU1396963A3 (de)
WO (1) WO1985003076A1 (de)
ZA (1) ZA85251B (de)
ZW (1) ZW385A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
ES2271247T3 (es) * 2001-02-27 2007-04-16 Migenix Corp. Aril-n-cianoguanidinas y metodo relacionados con ellas.
KR100898894B1 (ko) * 2001-11-05 2009-05-21 메르크 파텐트 게엠베하 히드라조노-말로니트릴
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (de) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
WO2007054514A2 (en) * 2005-11-14 2007-05-18 Boehringer Ingelheim Vetmedica Gmbh Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (de) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
MX2011005444A (es) 2008-11-25 2011-06-09 Boehringer Ingelheim Vetmed Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensibilizantes a iones de ca(2+) para el tratamiento de la cardiomiopatia hipertrofica.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
EP3167876B1 (de) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmazeutische tablettenformulierung für den veterinärmedizinischen sektor, verfahren zur herstellung und verwendung davon
EP3718557A3 (de) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylat-cyclase-rezeptoragonist sp-333 zur verwendung in der darmreinigung
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
DK3021832T3 (da) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
ES2593210T3 (es) 2013-12-04 2016-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
ATE13294T1 (de) * 1981-03-04 1985-06-15 Ciba Geigy Ag Pyridazinone, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und deren verwendung.
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones

Also Published As

Publication number Publication date
DK9185D0 (da) 1985-01-08
DD231350A5 (de) 1985-12-24
ES549629A0 (es) 1987-03-01
DK9185A (da) 1985-07-14
SU1396963A3 (ru) 1988-05-15
EP0150937A2 (de) 1985-08-07
EP0150937A3 (en) 1985-08-21
IL74031A0 (en) 1985-04-30
PT79819B (en) 1987-01-07
CA1260471C (de) 1989-09-26
CA1260471A (en) 1989-09-26
ATE37179T1 (de) 1988-09-15
RO92607A (ro) 1987-11-30
CN85101722A (zh) 1987-01-31
ES8607949A1 (es) 1986-06-01
JPS63313776A (ja) 1988-12-21
ES8706645A1 (es) 1987-07-01
PH22136A (en) 1988-06-01
DK162519C (da) 1992-03-30
AU3761185A (en) 1985-07-18
NZ210816A (en) 1987-06-30
IE850069L (en) 1985-07-13
KR850005417A (ko) 1985-08-26
ES539446A0 (es) 1986-06-01
AU572252B2 (en) 1988-05-05
PT79819A (en) 1985-02-01
DE3564941D1 (en) 1988-10-20
JPS60158181A (ja) 1985-08-19
JO1351B1 (en) 1986-11-30
PL147123B1 (en) 1989-04-29
GB8400863D0 (en) 1984-02-15
HUT37128A (en) 1985-11-28
CA1251209A (en) 1989-03-14
ES8703846A1 (es) 1987-03-01
IE57969B1 (en) 1993-06-02
CS248731B2 (en) 1987-02-12
WO1985003076A1 (en) 1985-07-18
MY100124A (en) 1989-12-18
PL251516A1 (en) 1985-12-17
KR920006781B1 (ko) 1992-08-17
GR850068B (de) 1985-05-03
FI850140A7 (fi) 1985-07-14
FI850140A0 (fi) 1985-01-11
JPS63313775A (ja) 1988-12-21
ZA85251B (en) 1986-08-27
ES554965A0 (es) 1987-07-01
DK162519B (da) 1991-11-11
EP0150937B1 (de) 1988-09-14
US4654342A (en) 1987-03-31
ZW385A1 (en) 1985-08-07
HU193591B (en) 1987-11-30
NO850129L (no) 1985-07-15
IL74031A (en) 1988-07-31

Similar Documents

Publication Publication Date Title
FI850140A0 (fi) Kemiska foereningar.
GB2071098B (en) Dibenzocycloheptenylidenes and antiinflammatory compositions
ATE67197T1 (de) Thiadiazinon-derivate.
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
SE8303410D0 (sv) Benzene derivatives, processes for their preparation and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: SMITH KLINE & FRENCH LABORATORIES